My latest clinical pipeline column for Nature Medicine is a look at a drug recently approved by the to delay the onset of type 1 diabetes.

It's a direct descendant of the very first monoclonal ever approved for clinical use.

nature.com/articles/d41591-022

Follow

Here's the fulcrum of this story, the paper where the Bluestone group and collaborators turn the mouse anti-human CD3 monoclonal into a chimeric, non-Fc activating molecule: Alegre et al, 1994

pubmed.ncbi.nlm.nih.gov/800958

Sign in to participate in the conversation
Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.